Keywords: CIS markets, Branded generics, Biosimilars, Russia, Ukraine, Kazakhstan, PMR

Changes in reimbursement to bring profits for branded generics in CIS markets

Article | 02 August 2012

Most of the Commonwealth of Independent States (CIS) markets do not have modern reimbursement policies, but the countries in question ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in